DLBCL is a particularly aggressive disease entity which is broadly characterized by recurrent gene aberration, including the relatively infrequent presence of MYC (8q24), BCL2 (18q21), and/or BCL6 (3q27) gene translocations/rearrangements [11,12,13,14,15,16,17]. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.